Momenta Pharmaceuticals (MNTA) PT Lowered to $16 at Barclays; 'More Conservative Stance on Eventual (Generic Copaxone 40mg) Market Share'
Tweet Send to a Friend
Barclays lowered its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $16.00 (from $17.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
